Discover trends, market shifts, and competitive outlooks for the peripheral neuropathy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Projected CAGR for the Peripheral Neuropathy Market Size from 2025 to 2034?

In recent years, there has been a rapid expansion in the market size for peripheral neuropathy. The market is set to escalate from a valuation of $4.09 billion in 2024 to around $4.62 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 13.2%. This significant growth during the historical period is mainly due to several factors. These include the rising prevalence of chronic ailments such as diabetes, increased consciousness regarding neuropathic pain management, global surge in the elderly population, continual improvement and expansion of healthcare infrastructure, the existence of specialized treatment facilities, initiatives taken by the government to enhance neurological health services, along with increasing inclination towards new treatment alternatives.

The market for peripheral neuropathy is poised for significant expansion in the coming years, with projections estimating its worth to reach $7.52 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.9%. This predicted progression throughout the forecast period can be linked to a surge in chronic diseases like diabetes and cancer, progression in medicines targeting neuropathic pain pathways, amplified research and development funding for novel treatment methods, adoption of digital health tools for remote supervision and personalized handling of neuropathic symptoms, an elevated emphasis on patient-focused care models, and enhanced accessibility to multidisciplinary healthcare provisions. Key market trends for the forecast period involve a rising preference for personalized treatment approaches, an increased usage of wearable technology for real-time tracking of neuropathic symptoms and treatment, widening of telemedicine facilities for distant consultations and follow-ups, creation of targeted therapies addressing distinct neuropathic pain pathways and mechanisms, progression in regenerative medicine techniques, merging of digital therapeutics platforms for cognitive behavioral therapy, mindfulness-based interventions, and technological evolution in diagnostic instruments for early identification and supervision of peripheral neuropathy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16507&type=smp

Which Primay Drivers Are Accelerating Growth in the Peripheral Neuropathy Market?

As the number of diabetes cases continues to rise, so too does the expansion of the peripheral neuropathy market. Diabetes is a long-lasting health issue that results in excessive blood glucose levels due to the body’s inability to manufacture or effectively utilize insulin. The growing incidence of diabetes is primarily driven by factors such as escalating obesity rates, less active lifestyles, and older age groups. Diabetic patients can develop peripheral neuropathy due to nerve damage caused by extended periods of high blood sugar, resulting in symptoms like aches, tingling sensations, and lack of sensation in the limbs. Proper blood sugar regulation is vital to halt or slow down the progression of this disorder. For instance, The British Diabetic Association, a UK diabetes charity, published a report in April 2023 stating that 4.3 million individuals in the UK have been diagnosed with diabetes. Compared to 2020-21, registration data for 2021-22 shows a rise of 148,951 cases. Additionally, over 2.4 million individuals in the UK are at a high risk of developing type 2 diabetes. Therefore, the increasing prevalence of diabetes is fuelling the ascendancy of the peripheral neuropathy market.

How Is the Peripheral Neuropathy Market Segmented?

The peripheral neuropathy market covered in this report is segmented –

1) By Type: Chemotherapy-Induced, Diabetic, Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated, Idiopathic

2) By Diagnosis: Blood Test, Biopsy, Imaging, Other Diagnosis

3) By Treatment: Medications, Antidepressants, Anti-Seizure Medication, Pain Reliever, Topical Treatment, Therapies, Nerve Stimulation, Plasma Exchange, Physical Therapy, Other Treatments

4) By End-User: Hospitals, Clinics, Ambulatory Centers

Subsegments:

1) By Chemotherapy-Induced: Taxane-Induced Peripheral Neuropathy, Platinum-Based Drug-Induced Neuropathy, Other Chemotherapy-Induced Neuropathies

2) By Diabetic: Type 1 Diabetes-Induced Peripheral Neuropathy, Type 2 Diabetes-Induced Peripheral Neuropathy

3) By Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS) Associated: HIV-Associated Peripheral Neuropathy, AIDS-Related Peripheral Neuropathy

4) By Idiopathic: Acute Idiopathic Neuropathy, Chronic Idiopathic Neuropathy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=16507&type=smp

Which Regions Are Key Players in the Growth of the Peripheral Neuropathy Market?

North America was the largest region in the peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Peripheral Neuropathy Market?

Key players in the peripheral neuropathy market are prioritizing the development of innovative solutions, including point-of-care devices, to enhance the diagnosis and treatment of this health issue. A point-of-care test for the quantitative screening of peripheral neuropathy serves a quick detection tool for nerve damage, especially in individuals suffering from diabetes. NeuroMetrix Inc., a producer of non-invasive medical equipment in the United States, for example, released their DPNCheck 2.0 point-of-care device designed for recognizing peripheral neuropathy in January 2023. This device, equipped with the nerve conduction technology, identifies systemic deterioration of peripheral nerves that could result in severe conditions such as diabetic peripheral neuropathy (DPN). It allows for fast screening of patients by quantitatively measuring peripheral nerve functionality, hence outperforming conventional methods like monofilament and fork tuning tests in terms of both speed and accuracy.

View the full report here:

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

How Is the Peripheral Neuropathy Market Defined and What Are Its Core Parameters?

Peripheral neuropathy refers to a condition characterized by damage or dysfunction of the peripheral nerves, which transmit signals between the central nervous system (the brain and spinal cord) and the rest of the body. This disorder can cause various symptoms, including numbness, tingling, weakness, and pain, typically in the hands and feet.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16507

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model